Evolus is a performance beauty company focused exclusively on cash-pay aesthetics. Its flagship product, Jeuveau®, is the fastest-growing neurotoxin in the U.S., capturing 13% market share in just five years. Evolus is now expanding its portfolio with Evolysse™, a line of unique injectable hyaluronic acid dermal fillers expected to launch in Q2 2025, marking the first major innovation in the filler market in over a decade.